These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2066688)

  • 21. [Androgen secretion in the polycystic ovary syndrome].
    Forti G; Giusti G
    Minerva Endocrinol; 1987; 12(3):199-202. PubMed ID: 2958688
    [No Abstract]   [Full Text] [Related]  

  • 22. Lecturing on polycystic ovary syndrome (PCOS).
    Kazer RR
    Semin Reprod Endocrinol; 1997 May; 15(2):193-4. PubMed ID: 9165663
    [No Abstract]   [Full Text] [Related]  

  • 23. Insulin as an effector of human ovarian and adrenal steroid metabolism.
    Nestler JE; Strauss JF
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):807-23. PubMed ID: 1778178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin and related peptides in hyperandrogenism.
    Adashi EY
    Clin Obstet Gynecol; 1991 Dec; 34(4):872-81. PubMed ID: 1778029
    [No Abstract]   [Full Text] [Related]  

  • 25. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
    Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
    Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome.
    Maas KH; Chuan S; Harrison E; Cook-Andersen H; Duleba AJ; Chang RJ
    Fertil Steril; 2016 Oct; 106(5):1252-1257. PubMed ID: 27473350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome.
    Schuring AN; Schulte N; Sonntag B; Kiesel L
    Gynakol Geburtshilfliche Rundsch; 2008; 48(1):9-15. PubMed ID: 18209494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Endocrinological environment in polycystic ovarian disease (PCOD)].
    Fujimoto S; Tanaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Sep; 40(9):1465-70. PubMed ID: 3049852
    [No Abstract]   [Full Text] [Related]  

  • 29. The polycystic ovary syndrome. 1. Pathogenesis.
    White MC; Turner EI
    Br J Hosp Med; 1994 Feb 16-Mar 1; 51(4):167-74. PubMed ID: 8012678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
    Nestler JE
    Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of testosterone and androstenedione porduction rates with dexamethasone in women with idiopathic hirsutsm and polycystic ovaries.
    Bardin CW; Hembree WC; Lipsett MB
    J Clin Endocrinol Metab; 1968 Sep; 28(9):1300-6. PubMed ID: 4300558
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Etiopathogenesis of the polycystic ovary syndrome].
    Sciarra F; Toscano V; Tosti-Croce C
    Minerva Endocrinol; 1987; 12(3):183-90. PubMed ID: 3116379
    [No Abstract]   [Full Text] [Related]  

  • 35. [Polycystic ovary syndrome: central or peripheral disorder of regulation?].
    Szilagyi A; Rossmanith WG
    Zentralbl Gynakol; 1991; 113(15-16):851-6. PubMed ID: 1746182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovary syndrome: androgens and hypertension.
    Reckelhoff JF
    Hypertension; 2007 Jun; 49(6):1220-1. PubMed ID: 17389256
    [No Abstract]   [Full Text] [Related]  

  • 37. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
    Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
    Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenal morphologic considerations in polycystic ovary syndrome.
    Gonzalez F; Speroff L
    Obstet Gynecol Surv; 1990 Aug; 45(8):491-508. PubMed ID: 2198502
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome.
    Gonzalez F; Chang L; Horab T; Lobo RA
    Fertil Steril; 1996 Sep; 66(3):354-61. PubMed ID: 8751729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of ovarian and adrenal sources of androgens in women with polycystic ovary syndrome. Dexamethasone and GnRH-agonist administration.
    Fulghesu AM; Lanzone A; Fortini A; Guido M; Caruso A; Mancuso S
    J Reprod Med; 1993 May; 38(5):387-92. PubMed ID: 8320677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.